

## Formulary Council Meeting Minutes

March 29, 2017

Present: Council Chair Kevin Wilson, ND; Council Members: Justin Bednar, RPh; Natalie Gustafson, PharmD; Dohn Kruschwitz, MD; Lissa McNiel, ND; Mary-Beth Baptista, Executive Director.

Excused absence: John Block, PhD

Meeting started at 9:30 am

### Approval of Minutes:

Discussion regarding recommendation for the board to write a rule to clarify that ND's can administer controlled substances for office use. Any drug should be properly stored and a record kept of administering.

Discussion regarding an administrative error of title of document: "June 13, 2016 Public Session Meeting Minutes." Electronic file reflects the document was mistitled and the document for approval was written on or about October, 10, 2016. Further, members recalled the discussion noted on page two regarding making amendments to administrative rules OAR 850-050-0100, 850-050-0190 occurred at the September Formulary Meeting during public session.

Motion to approve the September 2017 minutes, seconded, motion approved unanimously.

### Administrative Rules:

Rule 850-060-0226(8f) – Does not include barbiturates except for Phenobarbital needs to be changed.

Council member D. Kruschwitz made a motion to approve the new drugs on the drug list, council member J. Bednar seconded the motion, motion approved unanimously.

OAR 850-060-0223 - OBNM Board approved as an exclusionary rule. Formulary council recommends changing OAR 850-060-0226 classifications to reflect the change in 0223. Council recommended the Board amend OAR 850-060-0226 to refer to / include all AHFS pharmacological therapeutic classifications, except for the exclusions listed in OAR 850-060-0223. OAR 850-060-0225 would be eliminated.

This listing does not supersede the education and training requirement established in OAR 850-060-0212, IV agents or exclusion listed in OAR 850-060-0223. The Formulary Council may consider new agents in the future.

Motion and second to adopt alteration of underline (2a) of OAR 850-060-0223 – allowing barbiturates except phenobarbital and remove (2b) of OAR 850-060-0226 and to add mifepristone to 2d. Council member D. Kruschwitz made a motion to adopt, council member N. Gustafson seconded, motion approved unanimously.

Motion by Council member D. Kruschwitz and council member J. Bednar second, to eliminate the alphabetical list of the formulary compendium under OAR 850-060-0225, motion approved unanimously.

Motion and second to change OAR 850-060-0226 to state: “The Formulary Council has adopted the American Hospital Formulary Service current addition drug classification as defined by American Hospital Formulary Service drug information text. This listing does not supersede the education and training requirement established in OAR 850-060-0212, for administration of IV agents or exclusions listed in OAR 850-060-0223. Motion to adopt by Council member N. Gustafson, second by member J. Bednar, motion approved unanimously.

The next Formulary Council meeting is September 25, 2017.

Meeting adjourned at 11:32 am

## Formulary Council Meeting Minutes

September 25, 2017

Present: Formulary Council Chair Kevin Wilson, ND; Council Members: Justin Bednar, RPh; Natalie Gustafson, PharmD; Dohn Kruschwitz, MD; Lissa McNiel, ND; Adam Alani; Mary-Beth Baptista, Executive Director.

Meeting started at 9:30 am

### Approval of Minutes:

The March 29, 2017 minutes approved with one change, Adam Alani did not attend the March 29, 2017 meeting. Motion made to approve the March 29, minutes, motion approved unanimously.

### Administrative Rules:

OAR 850-060-0223 & OAR 850-060-0226 - The Board approved the change and the new rule is going through the rule making process.

OAR 850-030-0035 & OAR 850-040-0210 – At the August 2017 board meeting discussed reducing the CE hours and to also clean up the active/inactive license. Previous rule stated you can only carry over credits from programs attended in December that will change with the new rule, carry over credit of 15 hours each year discussed and a total of 32 hours of CE annually. Public hearing is scheduled for Thursday, October 19, 2017.

### Statement of Philosophy on Telemedicine:

Dr. Lissa McNiel gave the Formulary Committee an overview on the Statement of Philosophy on Telemedicine. The Board adopted the Statement of Philosophy on Telemedicine at the August 28, 2017 board meeting.

### Oregon Board of Pharmacy final proposed OAR 855-043-0505:

The final draft of this rule is in your meeting packet for review.

Dr. John Bloch is retiring is position on the Formulary Council and his spot will need to be filled. The Formulary Council will start the search for a replacement. An email will go out in January 2018 to all licensee regarding the open position and posted on the OBNM website.

### Adding Ketamine to the Formulary List:

The Formulary Council would like more information on usage for this drug and more research before making a final decision to add to the formulary list. This will be tabled until the March 2018 meeting.

The Formulary Council discussed ozone therapy CE. Chelation re-certification is every 5 years. It would be helpful to have re-fresher course/education on IV and chelation.

The next Formulary Council meeting is March 12, 2018 at 9:30 am.

Meeting adjourned at 11:00 am